- Home
- ZEPP vs ORKA Comparison
ZEPP vs ORKA Comparison
Compare ZEPP & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- ORKA
- Stock Information
- Founded
- ZEPP 2013
- ORKA 2004
- Country
- ZEPP Netherlands
- ORKA United States
- Employees
- ZEPP N/A
- ORKA N/A
- Industry
- ZEPP Computer Manufacturing
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ZEPP Technology
- ORKA Health Care
- Exchange
- ZEPP Nasdaq
- ORKA Nasdaq
- Market Cap
- ZEPP 696.3M
- ORKA 580.3M
- IPO Year
- ZEPP N/A
- ORKA N/A
- Fundamental
- Price
- ZEPP $49.94
- ORKA $16.35
- Analyst Decision
- ZEPP
- ORKA Strong Buy
- Analyst Count
- ZEPP 0
- ORKA 8
- Target Price
- ZEPP N/A
- ORKA $40.43
- AVG Volume (30 Days)
- ZEPP 599.0K
- ORKA 146.8K
- Earning Date
- ZEPP 08-03-2025
- ORKA 08-11-2025
- Dividend Yield
- ZEPP N/A
- ORKA N/A
- EPS Growth
- ZEPP N/A
- ORKA N/A
- EPS
- ZEPP N/A
- ORKA N/A
- Revenue
- ZEPP $199,947,000.00
- ORKA N/A
- Revenue This Year
- ZEPP $758.69
- ORKA N/A
- Revenue Next Year
- ZEPP N/A
- ORKA N/A
- P/E Ratio
- ZEPP N/A
- ORKA N/A
- Revenue Growth
- ZEPP N/A
- ORKA N/A
- 52 Week Low
- ZEPP $2.13
- ORKA $5.49
- 52 Week High
- ZEPP $55.62
- ORKA $31.13
- Technical
- Relative Strength Index (RSI)
- ZEPP 72.94
- ORKA 61.56
- Support Level
- ZEPP $36.35
- ORKA $14.70
- Resistance Level
- ZEPP $53.79
- ORKA $16.12
- Average True Range (ATR)
- ZEPP 5.75
- ORKA 1.00
- MACD
- ZEPP 0.42
- ORKA 0.06
- Stochastic Oscillator
- ZEPP 72.23
- ORKA 81.07
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.